查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750696

日本医药合约开发与製造组织市场：市场规模、份额、趋势分析（按产品、工作流程、应用、服务和最终用途）、细分市场预测（2025-2030 年）

Japan Contract Development & Manufacturing Organizations Market Size, Share & Trends Analysis Report By Product, By Workflow, By Application, By Service, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 127 Pages | 商品交期: 2-10个工作天内

价格

日本医药合约开发与製造组织市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，日本医药合约开发和製造组织市场预计到2030年将达到207.6亿美元，2025年至2030年期间的复合年增长率为7.77%。

生物製药需求成长、疾病负担加重、老年人口成长是主要成长要素。预测期内，各合约开发和製造组织 (CDMO) 对其设施和服务扩建的投资不断增加，可能会提振市场。

此外，製药公司不断增加的研发投入也推动了市场成长。随着製药公司加大研发投入，他们可能会寻求外部专业知识和资源来加速药物开发进程。 CDMO 提供药物开发、生产和测试方面的专业服务，对于希望委託方面研发活动的製药公司来说，它们无疑是宝贵的合作伙伴。目前已有多家公司投资医药研发活动。例如，药明康德于 2022 年 3 月推出了四环霉素相容于自惰性腺病毒 (TESSA) 技术，旨在加速用于细胞和基因治疗的药物用腺结合病毒的生产。

製药业中製药公司外包服务的增加正在对日本市场产生重大影响。製药公司外包的趋势是由获得对药品成功开发和商业化至关重要的新技术的价值所驱动的，这导致了製药业外包活动的增加。外包在製造方面具有显着的优势，包括提供专业知识、改善现金流管理以及降低投资风险。

值得注意的是，日本监管机构正在加速再生医学和基因治疗产品的核准。例如，《药品和医疗设备法》（PMD法案）、《21世纪治癒法案》以及「优先药物」（PRIME）计画的通过，帮助日本改善了再生医学的可及性。这些监管措施预计将促进日本再生医学的开发和生产需求。

日本药品合约开发与製造组织市场报告：重点

  • 2024年，原料药(API) 占据市场主导地位，市占率达 81.14%。该领域的成长主要源于市场对竞争性药物开发以及端到端合约开发与生产组织 (CDMO) 服务日益增长的需求。此外， 原料药製造技术的进步、生物製药行业的成长以及老年人口的成长也是推动该领域成长的主要因素。
  • 这是由于对生物相似药、学名药、再生疗法等药品的需求强劲。商用CDMO 可以透过提供知识、节省时间和成本效益来提供帮助。
  • 从应用角度来看，由于日本癌症发生率高，肿瘤学在2024年占据了日本CDMO产业的主导地位。再生产品和病毒疗法在癌症治疗中的核准进一步推动了市场成长，而全球癌症患者数量的增加也进一步推动了该产业的发展。此外，医药研发投入的增加、专利到期以及对抗癌药物和生物创新的需求也是推动肿瘤学产业成长的因素。

目录

第一章 分析方法与范围

第二章执行摘要

第三章：日本医药合约开发与製造组织市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 定价模式分析
  • 技术状况
  • 经营模式分析
  • 法律规范
  • 临床试验数量分析（2024年）
    • 各阶段临床试验总数（2024 年）
    • 按临床实验设计分类的临床试验总数（2024 年）
    • 按主要治疗领域分類的临床试验总数（2024 年）
  • 日本医药品合约开发与製造组织市场的分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章：日本医药合约开发与製造组织市场：按产品进行的估算与趋势分析

  • 细分仪表板
  • 日本医药合约开发製造组织市场：依产品波动分析
  • 日本合约开发製造组织 (CDO) 市场规模及产品趋势分析（2018-2030 年）
  • API
    • 种类
    • 合成方法
    • 药物
    • 製造方法
  • 製药
    • 依药物类型
    • 按类型
    • 按分子

第五章：日本医药合约开发与製造组织市场：依工作流程估算与趋势分析

  • 细分仪表板
  • 日本医药合约开发与製造组织市场：依工作流程的波动分析
  • 日本合约开发和製造组织 (CDO) 市场规模及趋势分析（按工作流程）（2018-2030 年）
  • 临床
  • 上市

第六章日本医药合约开发与製造组织市场：按应用的估计和趋势分析

  • 细分仪表板
  • 日本医药合约开发与製造组织市场：依应用进行趋势分析
  • 日本合约开发与製造组织 (CDO) 市场规模及应用趋势分析（2018-2030 年）
  • 肿瘤学
  • 荷尔蒙
  • 青光眼
  • 心血管疾病
  • 糖尿病
  • 其他的

第七章日本医药合约开发与製造组织市场：按服务分類的估计和趋势分析

  • 细分仪表板
  • 日本医药合约开发与製造组织市场：按服务分类的波动分析
  • 日本合约开发製造组织 (CDO) 市场规模及服务趋势分析（2018-2030 年）
  • 合约开发
  • 契约製造
  • 包裹
  • 品管与保证
    • 目视检查
    • 其他的
  • 其他的

第八章：日本医药合约开发与製造组织市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 日本医药合约开发与製造组织市场：依最终用途进行趋势分析
  • 日本合约开发与製造组织 (CDO) 市场规模及趋势分析（以最终用途）（2018-2030 年）
  • 製药公司
  • 生技公司
  • 其他的

第九章：日本药品合约开发与製造组织市场：竞争格局

  • 市场参与企业分类
  • 各公司市场占有率分析（2024年）
  • 公司简介
Product Code: GVR-4-68039-985-5

Japan Contract Development & Manufacturing Organizations Market Growth & Trends:

The Japan contract development and manufacturing organizations market size is estimated to reach USD 20.76 billion by 2030, expanding at a CAGR of 7.77% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.

In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.

The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market. The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.

Japan Contract Development & Manufacturing Organizations Market Report Highlights:

  • The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.14% in 2024. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
  • Based on workflow, the commercial segment held the largest market share in 2024, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
  • Based on application, the oncology segment dominated the Japan CDMO industry in 2024, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecasts timeline.
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Bottom Up Approach (Model 2)
    • 1.7.3. Value Chain Based Approach (Model 3)
    • 1.7.4. Multivariate Analysis (Model 4)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organizations Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Demand for Biopharmaceutical Drugs in Japan
      • 3.2.1.2. High Geriatric Population And Growing Disease Burden in Japan
      • 3.2.1.3. Low Cost Associated with Outsourcing Drug Manufacturing and Development Services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited Outsourcing Opted by Big Pharma Companies
      • 3.2.2.2. Quality Issues While Outsourcing
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Business Model Analysis
  • 3.6. Regulatory Framework
  • 3.7. Clinical Trials Volume Analysis, 2024
    • 3.7.1. Total Number of Clinical Trials, by Phase (2024)
    • 3.7.2. Total Number of Clinical Trials, by Study Design (2024)
    • 3.7.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.8. Japan Contract Development and Manufacturing Organizations Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL Analysis
    • 3.8.3. COVID-19 Impact Analysis

Chapter 4. Japan Contract Development and Manufacturing Organizations Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Japan Contract Development and Manufacturing Organizations Market: Product Movement Analysis
  • 4.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. API
    • 4.4.1. API Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Type
      • 4.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
        • 4.4.2.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
        • 4.4.2.2.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.3. Antibody Drug Conjugate (ADC)
        • 4.4.2.3.1. Antibody Drug Conjugate (ADC) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.4. Others
        • 4.4.2.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Synthesis
      • 4.4.3.1. Synthetic
        • 4.4.3.1.1. Synthetic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.4.3.1.2. Solid
          • 4.4.3.1.2.1. Solid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.4.3.1.3. Liquid
          • 4.4.3.1.3.1. Liquid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.3.2. Biotech
        • 4.4.3.2.1. Biotech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Drug
      • 4.4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.4.2. Innovative
        • 4.4.4.2.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.4.3. Generics
        • 4.4.4.3.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Manufacturing
      • 4.4.5.1. Continuous manufacturing
        • 4.4.5.1.1. Continuous Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.5.2. Batch manufacturing
        • 4.4.5.2.1. Batch Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Drug Product
    • 4.5.1. By Drug Type
      • 4.5.1.1. Oral Solid Dose
        • 4.5.1.1.1. Oral Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Semi-Solid Dose
        • 4.5.1.2.1. Semi-Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.3. Liquid Dose
        • 4.5.1.3.1. Liquid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.4. Others
        • 4.5.1.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. By Type
      • 4.5.2.1. Innovative
        • 4.5.2.1.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.2. Generic
        • 4.5.2.2.1. Generic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. By Molecule
      • 4.5.3.1. Small Molecule
        • 4.5.3.1.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. Large Molecule
        • 4.5.3.2.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organizations Market: Workflow Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Japan Contract Development and Manufacturing Organizations Market: Workflow Movement Analysis
  • 5.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
  • 5.4. Clinical
    • 5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Commercial
    • 5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organizations Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Japan Contract Development and Manufacturing Organizations Market: Application Movement Analysis
  • 6.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Hormonal
    • 6.5.1. Hormonal Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Glaucoma
    • 6.6.1. Glaucoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Cardiovascular Diseases
    • 6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Japan Contract Development and Manufacturing Organizations Market: Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Japan Contract Development and Manufacturing Organizations Market: Service Movement Analysis
  • 7.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 7.4. Contract Development
    • 7.4.1. Contract Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Contract Manufacturing
    • 7.5.1. Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Packaging
    • 7.6.1. Packaging Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Quality Control and Assurance
    • 7.7.1. Quality Control and Assurance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Visual Inspection
      • 7.7.2.1. Visual Inspection Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Others
      • 7.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Japan Contract Development and Manufacturing Organizations Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Japan Contract Development and Manufacturing Organizations Market: End Use Movement Analysis
  • 8.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Biotechnology Companies
    • 8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Japan Contract Development and Manufacturing Organizations Market: Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Company Market Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. LabCorp
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Wuxi AppTec, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Recipharm AB
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Samsung Biologics
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Catalent, Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. CordenPharma International
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Cambrex Corporation
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Thermo Fisher Scientific, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. FUJIFILM Diosynth Biotechnologies
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Sumitomo Chemical Company, Limited
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. CMIC HOLDINGS Co., LTD.
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Bushu Pharmaceuticals Ltd.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Nipro Corporation
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Japan Contract Development and Manufacturing Organizations Market, By Product, 2018 - 2030 (USD Million)
  • Table 4 Japan Contract Development and Manufacturing Organizations Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 5 Japan Contract Development and Manufacturing Organizations Market, By Application, 2018 - 2030 (USD Million)
  • Table 6 Japan Contract Development and Manufacturing Organizations Market, Service, 2018 - 2030 (USD Million)
  • Table 7 Japan Contract Development and Manufacturing Organizations Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 ADC Approvals in Japan
  • Table 9 Financial Performance
  • Table 10 Key company initiating service launches/upgrades
  • Table 11 Key companies initiating service launches/upgrades
  • Table 12 Key companies initiating partnerships
  • Table 13 Key companies initiating expansion
  • Table 14 Key companies initiating expansion

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market Research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Japan contract development and manufacturing organizations market segmentation
  • Fig. 7 Market driver analysis
  • Fig. 8 Market restraint relevance analysis
  • Fig. 9 Porter's five forces analysis
  • Fig. 10 PESTEL by SWOT analysis
  • Fig. 11 Regional marketplace: Key takeaways
  • Fig. 12 Japan synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Japan solid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Japan liquid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Japan biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Japan Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Japan Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Japan Antibody Drug Conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Japan continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Japan batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Japan oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Japan semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Japan liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Japan small molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Japan large molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Japan clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Japan commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Japan oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Japan hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Japan contract development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Japan packaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan quality control and assurance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan visual inspection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)